Table 3. Disease progression of 167 patients with essential thrombocythemia according to the mutational status of JAK2 and CALR.
| Characteristics | JAK2+/CALR+ (A) | JAK2+/CALR- (B) | JAK2-/CALR+ (C) | JAK2-/CALR- (D) | P value* | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| AvsB | AvsC | AvsD | BvsC | BvsD | CvsD | |||||
| Disease progression (%) in 4 groups | 1/7(14.3) | 9/103(8.7) | 0/19(0.0) | 0/38(0.0) | 0.708 | 0.157 | 0.480 | 0.171 | 0.217 | N/A |
| Disease progression (%) in 2 groups (JAK2+ vs JAK2-) | 10/110(9.1) | 0/57(0.0) | 0.060 | |||||||
N/A, not applicable.
*
P values were calculated using the Mann-Whitney U test.